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ABSTRACT  The EGFR/Erb-B receptor tyrosine kinases each play distinct and complementary 
roles in normal breast development. The four receptors form both homodimers and heterodimers 
in response to binding by ligands which show selectivity for one or more of the receptors (except 
Erb-B2). Together with the additional ﬂexibility generated by the formation of different dimer pairs, 
these signalling networks play key roles in directing a variety of both autocrine and paracrine cellular 
responses. Complex two-way interactions between mammary epithelial cells and the surrounding 
stroma direct proliferation, duct formation, branching and terminal differentiation during puberty, 
pregnancy and lactation, with each receptor and ligand fulﬁlling distinct roles. Caricatures of the 
normal role of EGFR/Erb-B signalling resulting in aberrant cellular responses are seen in breast 
cancers, where over-expression and/or (less commonly) mutation of one or more of the receptors 
results in enhanced cell proliferation, motility, release of proteases and angiogenic factors. Given 
their importance in tumour progression and their links with resistance to chemotherapy and 
anti-endocrine therapy, Erb-B receptors (most notably Erb-B2) have been exploited as therapeutic 
targets. Monoclonal antibodies (e.g. trastuzumab, pertuzumab) and small molecule tyrosine kinase 
inhibitors (e.g. lapatinib, afatinib) have shown signiﬁcant clinical responses in some breast cancer 
subtypes. Additional approaches include targeted toxins or drugs, peptide vaccines, immunRNase 
and chaperone inhibitors to deplete Erb-B2 protein levels. Greater understanding of the full spec-
trum of Erb-B-mediated signalling pathways and their misregulation in breast cancer will provide 
additional strategies to control malignant progression.
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The EGFR/ERB-B/HER family
The epidermal growth factor receptor (EGFR) and its close 
relatives HER2/c-Erb-B2, Erb-B3 and Erb-B4 are type 1 transmem-
brane receptor tyrosine kinases (RTK) with key roles in embryonic 
development, tissue renewal/repair and cancer. A great deal has 
been learned about their structure, signalling pathways and aber-
rations linked to malignant transformation since the explosion of 
interest in this family in the 1980’s.
Early discoveries
?????? ? ?????? ????????????? ??????? ???? ?????? ?????????????
??????????????????????????????????????????????????????????????????
regulated eyelid opening in mice, and as the binding partner for 
?????????????????????????????????????????????????????????????
EGFR was found to have kinase activity when stimulated with 
ligands and to be capable of phosphorylating tyrosine residues on 
both itself and downstream targets. Even before EGFR was identi-
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TEB, terminal end bud; TGF?, transforming growth factor alpha; TN(BC), triple 
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???????????????????????????????????????????????????????????????????
growth factor, even though it is a mitogen for mesenchymal cells 
too) could be important in breast development as it stimulated 
growth of mouse mammary gland explants. The role of EGFR was 
later proved by showing impaired mammary gland development in 
mice harbouring EGFR mutations (Cohen, 1997).
Structure and function
Erb-B ???????????????????????????????????????????????????????
(ligand-receptor) layer, an intermediate signalling core processing 
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?????? ??? ????????????????? ????????????????????????????? ??? ??? ??????
cellular responses (Citri and Yarden, 2006).
All Erb-B receptors consist of an extracellular domain which binds 
ligands (except in the case of Erb-B2), a transmembrane region and 
a cytoplasmic domain with kinase activity. Although there are 10 
possible combinations of Erb-B dimers, not all are fully biologically 
active. Erb-B2 has no known ligands, but is the preferred partner 
of all family members, due to an intrinsically extended interaction 
loop rendering it constitutively available for dimerisation. Erb-B2 
can stabilise EGFR in a conformation that potentiates dimerisation 
and phosphorylation in the absence of ligand and alters endo-
???????????? ?????????????? ?????????????????????????????? ??????????????
transactivation of EGFR can be achieved by ligand-independent 
intracellular mechanisms, such as G protein-coupled receptor 
(GPCR) stimulation of Src or elevated calcium levels (Prenzel et 
al., 2000). Finally, the receptors interact with, and are modulated 
by, steroid hormone receptors and co-receptors. Erb-B3 was 
generally accepted to be kinase dead due to the lack of several 
key functional residues including the catalytic base aspartate, but 
a recent paper suggests that it nevertheless retains the ability to 
transphosphorylate its own intracellular domain (Shi et al., 2010). In 
any event, it can certainly form a very active signalling complex with 
all other EGFR RTK, especially Erb-B2. There is a high degree of 
homology in the kinase domain of the four receptors (59-81%) but 
more divergence in the C-terminal domains (only 11-25% identity). 
In addition to cross-talk between members of the EGFR/Erb-B 
?????????????????????????????????????????????????????? ?????????? ???
such as c-MET and IGF-1R, and it is possible that such alternative 
signalling pathways are linked to resistance to targeted therapies 
(Jin and Esteva, 2008). Erb-B receptors also integrate signals from 
the extracellular microenvironment by forming macromolecular 
clusters with integrins and tetraspanins in specialised membrane 
microdomains (Alexi et al., 2011)
Ligands
There are up to 13 recognised ligands of the EGFR family: EGF 
itself, heparin-binding (HB)-EGF, transforming growth factor (TGF)?, 
amphiregulin (AREG) epiregulin (EREG), epigen (EPG), betacellulin 
(BTC) and neuregulins (NRG) 1-6 (also known as heregulins), which 
have multiple splice variants. EGF and TGF? are the key EGFR 
binding ligands, BTC can bind and activate all receptors, and the 
NRGs have a preference for Erb-B3 and Erb-B4. All EGF family 
ligands exist as membrane-anchored precursors and are cleaved 
by metalloproteases (mainly ADAMs) resulting in ectodomain 
shedding and the release of soluble factors. The cleaved products, 
particularly of HB-EGF, have been implicated in transactivation of 
adjacent Erb-B receptors, and the remaining intracellular carboxy-
terminal fragments may have additional intracellular signalling 
functions (Higashiyama et al., 2008). The EGFR ligand shedding 
????????????????????????????????????????????? ???????????????
factors, including cytokines which bind G-protein couple receptors, 
activating PKC and MAPK signalling pathways (in the so-called 
triple membrane-passing signal mechanism) or via Wnt ligands 
binding Fzd receptors. Uncleaved, membrane-bound ligands can 
also stimulate adjacent cells via a juxtacrine mechanism which may 
be particularly important in epithelial-stromal communication. There 
???????????????????????????????????????????????????????????????????
EGFR phosphorylation and dictate the duration of signalling events 
and divergent cellular responses. For example, TGF? and AREG 
are more potent stimulators of motility and invasion than EGF. This 
is reportedly due to sustained activation of PLC? and MAPK by the 
????????????????????????????????????? ?????????????????????????
and degradation of EGFR.
Downstream signalling
Ligand binding induces conformational rearrangements of the 
receptors to expose the interaction loop, promoting association 
of both homodimers and heterodimers, followed by internalisation 
and/or phosphorylation events. The phosphorylated (activated) 
receptors act as docking points for a number of direct substrates 
????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????
patterns of binding partners, although each may be recruited to 
?????????????????????????????????????????????????????????????????????
????????????????????????? ??????????????????????????????????????
the mode of activation and the dimerisation partner (Schulze et 
al.?????????????????????????????????????????????????????????????????????-
sponses to external stimuli in different microenvironmental contexts 
and the integration of stimuli into co-ordinated cellular functions.
????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????-
tion (Schulze et al., 2005). Interestingly, EGFR and Erb-B4, the 
only fully functional receptors (in contrast to Erb-B2 and Erb-B3) 
????????????????????????????????????????????????????????????? ?????
functions in different cellular contexts in response to their preferred 
ligands (EGF family and NRGs respectively). 
Erb-B3 is activated primarily by NRG-1 and -2 and is a strong 
activator of the PI3 kinase pathway, having six binding sites for 
the p85 regulatory subunit. The PI3 kinase pathway is a pivotal 
point in cell signalling (mainly via AKT and mTOR) regulating cell 
size, metabolism, survival and proliferation. Negative regulation 
of pro-apoptotic and growth inhibitory pathways is mediated via 
FOXO transcription factors and GSK3?. There are additional links 
to promotion of motility via Rac and Rho, and angiogenesis via 
activation of HIF-1?.
In summary, the major signalling pathways activated by EGFR-
Erb-B receptors are mediated by PI3 kinase, Ras-Raf (MAPK), JNK, 
PLC? and result in a plethora of biological functions. Although initially 
termed “growth” factors, the ligands induce not only cell proliferation 
but also alter adhesion and motility and protect against apoptosis 
at the cellular level, and promote invasion and angiogenesis at the 
physiological level. Given that these signalling systems are critical 
in development, it is not surprising that their activation should result 
in multiple co-ordinated cell- and tissue-level responses in normal 
cells, but these are subverted by overexpression/misregulation in 
pathological processes such as cancer.
Roles in normal breast development
Much of our understanding of the functions of the Erb-B family 
in development has come from rodent models. EGFR is of course 
best known as the epidermal growth factor receptor and is primar-
?????????????????????????????????????????????????????????????????
other three family members are important for the development and 
maintenance of the cardiovascular and nervous systems, but also 
play complementary roles in breast development. Most of the Erb-B 
family receptors and their ligands are expressed in the mammary 
gland at some time during development, maturation and involu-
tion (Fig. 1). The precise and co-ordinated roles of the receptors 
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and their ligands are to some extent confounded by spatial and 
temporal complexities, a degree of redundancy, and many layers 
of regulation. Nevertheless, those functions that have been elu-
cidated have proved informative for the better understanding of 
?????????????????????????????????????????????????????????????????
The mammary gland is an unusual organ in that most of its 
development occurs not in embryonic development, but at puberty, 
stimulated by steroid hormones. Interestingly, the rudimentary em-
??????????????????????????????????????????????????????????????????
differentiation are orchestrated by signals from the surrounding 
stroma; indeed mammary epithelial cells can be completely re-
directed (e.g. toward salivary gland morphology and function) by 
placing them in association with mesenchymal cells from different 
tissues. 
The earliest phases of breast development are oestrogen inde-
pendent. In adolescence, oestrogen and oestrogen receptor (ER)? 
induce the next stage of branching, and in the adult progesterone 
ADAM17 null mice show the same developmental 
defects as those lacking TGF-?, or HB-EGF, suggest-
ing that this protease is primarily responsible for their 
processing and cleavage (Sahin et al., 2004). Further 
evidence of its physiological importance in mammary 
development was provided by its appropriate localisa-
tion in the gland (although this was also the case for 
many other ADAMs). However, the reciprocal lack of its 
sole inhibitor (TIMP3) in TEBs suggests that ADAM17 
would be active in areas of active ductal development. 
The means by which EGFR-activated stromal cells 
induce mammary epithelial development has also 
been intensively studied but it still not fully elucidated. 
??????????????????????????????????????????????????????
?????? ?????????????? ??????????????????? ?? ???????????????
differentiation) it is likely that many simultaneous cel-
lular responses are elicited. MT1-MMP (MMP14) is 
enriched in stroma surrounding TEBs and its activity, 
like that of ADAM17, would be enhanced by the lo-
cal downregulation of TIMP3. MMP14 may stimulate 
ductal branching by activating MMP2 and degrading 
collagen 1. However it is membrane-bound and could 
????? ????????? ??????????? ?????? ???????????? ???????????
defects in TEBs in Erb-B2-/- mammary epithelium 
???????????????????????????????????????????????????
penetration into the fatpad, secondary to misregulation 
of matrix metalloproteinases, since branching mor-
??????????????????????????????????????????????
secondary and tertiary branching. Another potential 
contributory mechanism is signalling via FGFR2 on 
mammary epithelial cells stimulated by stromal FGF10 
providing both mitogenic stimuli and guidance cues 
for ductal development (Sternlicht and Sunnarborg, 
2008) (Fig. 2).
Other Erb-B family members: additional roles in 
later mammary differentiation
AREG becomes strongly repressed during preg-
?????? ???? ?????????? ????????? ??? ???? ????????? ????
alveolar development. Erb-B2 in the epithelium is 
??????????????????????????????????????????????????
and its functional partner is thought to be Erb-B3, 
Puberty               Signalling              Biological responses
Maturity
Pregnancy
Lacta?on
Fat pad
duct
TEBs
Branching 
ducts
Alveolar 
buds
Mature
alveoli 
EGFR   ++++
Erb-B2 ++++ 
Erb-B3 +/-
Erb-B4 +/-
EGFR   +++
Erb-B2 ++++ 
Erb-B3 ++ 
Erb-B4 -
EGFR   ++
Erb-B2 ++
Erb-B3 ++++
Erb-B4 ++++
EGFR   ++
Erb-B2 ++
Erb-B3 ++++
Erb-B4 ++++
? Stromal cells (EGFR+)  stimulated by 
AREG induce MEC  proliferation and ductal
elongation
? FGFs, by binding to FGFR on MEC, may
serve as guidance cues for duct formation 
? Fat pad ‘invasion’ by ducts is potentiated
by proteases, upregulated by EGFR/Erb-B2
? MMPs activated by EGFR-MT1-MMP
stimulate branching  
? Erb-B2 and Erb-B3 regulate ductal branching
density and morphology
? Erb-B2 controls TEB development via a role
in cellular compartmentalisation 
? Erb-B3 also influences TEB development via
different complementary mechanisms
? AREG is strongly repressed
? Erb-B3 is  important in morphogenesis, 
signalling via PI3K
? Erb B2 heterodimers respond to NRG1 in
alveolar development
? Erb-B4  is required for  lobuloalveolar
development (activated via NRG1??)
? AREG is strongly repressed
? Erb-B2/B3/B4 heterodimers are required for
lactation
? Erb-B4 sustains differentiation and milk  
production via Stat5 in luminal progenitor MEC
? Erb-B4 soluble intracellular fragment signals
are important
Fig. 1. Differential roles of EGFR/Erb-B receptors and ligands during normal mammary 
gland development and maturation. The Figure illustrates the time- and differentiation-
dependent expression of the four Erb-B receptors and key ligands at puberty and during 
adult breast maturation, pregnancy and lactation. Their contrasting roles in ductal outgrowth, 
terminal end-bud (TEB) development, alveolar maturation and lactation are shown, and 
differential expression in epithelial and stromal cells is highlighted.
(PRG) plays a key role. The major contribution of Erb-B recep-
tors is during puberty, pregnancy and lactation, when the steroid 
hormones upregulate production of many growth factors, including 
those of the EGF family. 
EGFR signalling and the role of proteolytic regulation of ligands
Both EGF and TGF? in vitro and under certain circumstances 
in vivo can stimulate growth of mammary epithelium and ductal dif-
ferentiation. However, careful genetic knockdown, array and in situ 
?????????????? ??????? ?????????????? ?????????? ???? ?????? ????????
not the only) physiologically relevant ligand in vivo. What is more, 
it is strongly induced by oestrogens. Mammary morphogenesis 
??????????????????????????????????????????????????????????????
epithelial cells, its activation of EGFR on adjacent stromal cells, 
(particularly those immediately adjacent to developing ductal end 
buds) and then reciprocal inductive signals back to the epithelium 
(Sternlicht and Sunnarborg, 2008) (Fig. 2). 
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since knock-out of either gene results in similar abnormalities in 
these processes. 
Erb-B3 appears when mammary glands mature and Erb-B4 is 
only expressed during pregnancy and lactation. In Erb-B3-/- mice, 
there was a decrease in the size of TEBs but increases in branch 
density and the number of TEBs. This was associated with an 
increase in apoptosis but no change in cell proliferation rates in 
TEBs. The major signalling pathway activated by Erb-B3 in this 
context seems to be PI3 kinase (Stern, 2008). Nrg3 polymorphisms 
can also result in abnormalities in rodent mammary gland develop-
ment, also likely via activation of Erb-B3. Thus Erb-B3 plays a key 
role in regulating morphogenesis of mammary epithelium (Fig. 1). 
During pregnancy and lactation, Erb-B2, in association with its 
??????????????????????????????????????????????????????????????????
differentiation and milk protein production. Erb-B4 is essential for 
lobuloalveolar development and for maintaining lactation report-
edly via Stat5a. The ligand(s) responsible for activating Erb-B4 in 
??????????????????????????????????????????????????????????????
HRG1? has been implicated. Most of Erb-B4’s functions in the 
mammary gland seem to be mediated by a soluble intracellular 
fragment (4ICD). This fragment can localise in mitochondria and 
nuclei, eliciting different functional responses in cells. The 180 kDa 
membrane-bound Erb-B4 is cleaved by ADAM17, releasing a 120 
kDa ligand-binding ectodomain and an 80kDa transmembrane 
peptide (m80) with kinase activity (Blobel et al., 2009). The latter 
in many cancers, including breast, linked to a 
multiplicity of molecular mechanisms including 
??????????????? ???? ??? ????? ????????????? ???
epigenetic mechanisms, activating mutations 
of the receptors themselves or activation in-
duced by autocrine/paracrine ligands. EGFR is 
???????????????????????????????? ???????????????
other TKR, and also heterologous receptors such 
as GPCR via Src. Recently a novel mechanism 
of EGFR signalling has been suggested: EGF-
induced translocation to the nucleus associated 
with p-Tyr-1068 and indirect binding to DNA via 
STAT3 enabling EGFR to act as a transcriptional 
regulator of genes such as cyclin D1 and iNOS 
- discussed in (Burness et al., 2010).
Links to breast cancer
All of the four receptors are overexpressed to 
varying degrees in breast cancer, with their promi-
nence being in rank order Erb-B2>EGFR>Erb-
B3>Erb-B4. Many ligands, including NRG splice 
variants are also overexpressed, suggesting the 
possibility of autocrine signalling, although the 
combined measurement of EPG and NRG4 were 
the strongest predictors of relapse free interval 
and overall survival (McIntyre et al., 2010).
EGFR
Many early reports of expression/overexpres-
sion of EGFR and its ligands in breast cancer 
and links to prognosis were contradictory as 
they were largely based on immunohistochemi-
cal data and did not necessarily address the 
activation state of the signalling pathway. More 
Fig. 2. EGFR/Erb-B signalling linked to epithelial cell-stromal cell interactions in ductal 
development in the mammary gland. The Figure illustrates the reciprocal interactions be-
tween stromal cells and mammary epithelial cells (MEC) during normal development. ADAM 
sheddases, regulated by oestrogens, release ligands such as AREG which stimulate EGFR on 
neighbouring stromal cells. Additional proteases (e.g MMP2 activated by MT1-MMP) release 
growth factors which reciprocally stimulate MECs to proliferate. MMPs are also required for 
ductal ‘invasion’ into the fat pad. Adapted from (Sternlicht and Sunnarborg, 2008).
fragment is released from the membrane by presenilin-dependent 
?-secretase cleavage. Cleavage can be stimulated by ligand bind-
ing (generally HRG, HB-EGF or BTC) or simply in response to 
Erb-B4 overexpression. 
Nuclear 4ICD in secretory mammary epithelium signalling via 
Stat5a is thought to be the major driver of lactation since Stat5a 
transcriptionally regulates ?-casein and whey acidic protein (WAP) 
promoters. The proposed mechanism is as follows: Erb-B4 when 
activated becomes phosphorylated at Y964, providing a docking site 
for Stat5a SH2 domains. The following regulated intra-membrane 
proteolysis (RIP) previously described results in liberation of the 
4ICD-Stat5a complex and its translocation to the nucleus. It has 
been suggested that the 4ICD simply acts as a Stat5a chaperone, 
but may also serve as a regulator of transcription (Jones, 2008) 
or indeed have intrinsic independent transactivation activity. The 
4ICD fragment also functions as a selective ER? co-activator since 
it regulates expression of PGR, SDF-1 and Erb-B4 itself. This 
involves ER? recruitment not to canonical ERE sites but to AP-1 
sites in a complex with c-Jun (DeNardo et al., 2007). In contrast, 
cytosolic 4ICD may have different functions, which may explain 
????? ?????? ?????????? ????????????? ???????? ??????????????????????
to breast cancer biology.
Mutations and mechanisms of activation
Deregulation of Erb-B signalling pathways has been described 
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recent gene expression analyses and also functional studies have 
??????????????????????????? ???? ?????????????????????????????????
subsets (Foley et al., 2010). 
????????????????????????????????????????????????????????????????
in some cases (e.g. metaplastic subtype) (Burness et al., 2010) 
??????? ???? ?????? ??????????????? ?? ??????? ??????????????????????
breast cancers, a subset of triple negative breast cancers (TNBC; 
i.e. lacking ER, PGR or Erb-B2). TNBCs represent 10-17% of all 
breast cancers, are more common in certain non-Caucasian ethnic 
groups (e.g. those of African descent) and tend to occur at less than 
50 years of age. These cancers are also generally of high grade 
and show distinct patterns of metastasis; notably visceral, liver and 
brain involvement leading to particularly poor prognosis (Dawson 
et al., 2009). EGFR expression was found to be higher in patients 
with nodal or distant metastases than in those without (Sutton et 
al., 2010). Also, TGF? and NRG2? and the proteases responsible 
??????????????????????????????????????????????????????????????????
ER- cancers (suggesting autocrine signalling) whereas AREG 
is expressed in ER+ cancers and may rather promote paracrine 
activation via the stroma (Foley et al., 2010).
TNBC is particularly prevalent in women carrying a BRCA1 
mutation and EGFR overexpression is found in 67% of BRCA1 
related cancers vs ~ 18% of sporadic cancers. Using human mam-
mary epithelial cell (hMEC) cultures it was shown that even partial 
suppression of BRCA1 function (using RNAi) could induce EGFR 
expression and an increase in EGFR+ cancer stem-like cells, 
suggesting that this receptor could provide a growth advantage at 
early stages of transformation. Treating (MMTV-Cre) BRCA1????????
p53+/-???????????? ???? ???????? ?????????????? ????????? ????????????
increased the latency period before mammary tumours developed, 
although this was limited to ER- and not ER+ subtypes (Burga et 
al., 2011). These data suggest that early intervention with EGFR 
??????????? ?????? ??? ?????????? ???BRCA1 mutation carriers in a 
preventive setting. However, in established cancers, clinical trials 
to date have not shown major responses in unselected patient 
populations (Burness et al., 2010). 
???????????????????????????????????????????????????????????????
majority of patients having disease in their lymph nodes and over 
one third with distant metastases at the time of diagnosis. It is 
?????????????????????????????????????????????????????????????????
of RhoC GTPase (resulting in a highly angiogenic phenotype) and 
a hyperactivated MAPK signalling path which has been linked to 
overexpression of EGFR and Erb-B2 (Van Laere et al., 2007). 
EGFR has also been implicated as a key player in the mitogenic 
and motogenic effects mediated by the HGF-c-MET signalling axis 
in breast cancer. HGF and/or c-MET expression increase with 
tumour progression and each is independently associated with 
poor prognosis. Cross-talk between these RTK has been identi-
????????????????????????????? ???? ????????????????????????? ????
and conversely EGFR ligands activating c-MET via intracellular 
signalling pathways. EGFR inhibitors have been shown to attenu-
ate HGF-mediated proliferation, motility and invasion of several 
breast cancer cell lines in vitro.
Erb-B2
Neu?? ???? ???? ?????????? ??? ???????? ???? ????? ?????????? ??? ??
chemically-induced neuroblastoma and shown to be similar to a 
??????????? ????????????????????????????? ????? ???????? ??????????
?????????????????? ?????????????? ?????? ?? ?????? ???????? ?????
it is associated with poor prognosis, although it is an early event 
occurring in over half of in situ carcinomas. Interestingly, an Erb-B2 
subtype clearly emerged from a genetic analysis of breast cancer 
??????????????????????????????????????????????????????????????????
properties (Sorlie, 2004). Breast cancers may express between 
25-50 copies of the ERB-B gene resulting in up to 2 million recep-
tors per cell. This differential provides a relatively tumour-selective 
therapeutic target, as levels are absent or low in most normal adult 
tissues. One exception is the heart, which may explain some of the 
cardiomyopathies seen with Erb-B targeted therapies, particularly 
when they were administered with anthracyclines, which is no longer 
a recommended combination (Procter et al., 2010). 
???????????????? ??????? ???? ???? ?????? ?????????? ???????????
including increased sensitivity to doxorubicin (perhaps because 
the HER2????????????????????????????????????????????????????????
doxorubicin) and relative refractoriness to anti-endocrine agents 
(partly due to an inverse relationship between Erb-B2 and ER? ex-
pression levels). It has been suggested that Erb-B2+ breast cancers 
may be especially prone to post-surgical recurrences due to their 
??????????????????????????????????????????????????????????????????
this could be prevented by trastuzumab. However, only a subset of 
Erb-B2+ breast cancers responds to trastuzumab, suggesting ad-
ditional levels of complexity. Recently, more detailed analyses have 
revealed not only genetic heterogeneity within Erb-B2+ tumours, 
?????????????????????????????????????????? ???????????????????????
levels of hypoxia-regulated genes show characteristics of basal 
cancers, and those without behaved more like luminal cancers, 
showing that even oncogenic drivers such as Erb-B2 are susceptible 
to modulation by the host microenvironment (Gatza et al., 2011). 
Erb-B3
In mouse mammary carcinoma models induced by PyVMT or 
mutated or overexpressed neu, ???????????????????????????????????
found in association with Erb-B2, again attesting to the effective 
???????????? ??????? ??????? ? ?????????? ???????????? ?????????????
????????????????????????????????????????????????????????????????????
lapatinib: response has been associated with inhibition of Erb-B3 
and AKT phosphorylation. In contrast resistance has been linked 
with a de novo point mutation in Erb-B2. In a panel of six Erb-B2-
overexpressing human tumour cell lines, Erb-B3 knockdown by 
RNAi was as effective as Erb-B2 knockdown at inhibiting prolifera-
tion in vitro, and xenograft tumour growth in vivo, whereas EGFR 
expression was dispensable. Preferential phosphorylation of Erb-B3 
was also seen in Erb-B2+ human breast cancers, suggesting a 
pivotal role for Erb-B3 in Erb-B2-driven tumours (Stern, 2008).  
Erb-B3 is overexpressed in around 10% of breast cancers, 
??????????????????????????????????????????????????????????????
????????? ???????????????????? ??? ??????? ?????????? ????????????????? ???
must function solely as a key dimerisation partner, although it can 
become phosphorylated by other receptors. The phosphorylated 
form strongly activates the PI3 kinase pathway as it contains mul-
tiple binding sites for the p85 regulatory subunit. In some studies 
Erb-B3 expression seemed to correlate with ER positivity and was 
associated with longer overall survival. There is a stronger associa-
???????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????
cannot be excluded. There are thought to be important but poorly 
understood roles for nuclear localization and secreted isoforms 
such as p85 soluble Erb-B3, akin to the p95Erb-B2 ECD. The 
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disparate results reported could also be related to the subcellular 
localisation of Erb-B3 and its activation status, which in turn are 
regulated by ligand availability.
Erb-B4
There are contradictory data on the role of Erb-B4 in breast 
cancer since both positive and negative associations with prognosis 
have been described; also the full-length and cleaved (4ICD) splice 
variants may have different functions (Sundvall et al., 2008). It is 
reportedly associated with luminal A breast cancer subtypes (which 
have a better prognosis than other groups) perhaps linked to its role 
in differentiation. It is also generally associated with positive ER 
status and hence has been predicted to be oestrogen regulated. In 
support of this is the fact that its promoter contains three possible 
oestrogen response element half-sites and oestrogen recruits ER? 
to one of these sites.
Inhibition of Erb-B4 expression can inhibit the proliferation of ER+ 
breast carcinoma cell lines, suggesting a growth promoting effect 
that is ER?-dependent and reliant upon cross-talk between these 
two signalling pathways. Other Erb-B family members also show 
reciprocal interactions, with mechanisms that include phosphoryla-
tion of ER? or its co-activators, linked to ER?-induced upregula-
tion of Erb-B ligands and a fostering of autocrine signalling loops. 
However, the Erb-B4 mechanism involving interactions between a 
???????????????????????????????????????????????
Paradoxically, stimulation of ER+ breast cancer cells with Erb-
B4 ligand, however, can result in cell death, even though it is also 
dependent on proteolytic release of 4ICD. It has been proposed 
that, since this activity is independent of nuclear localisation, it may 
be the result of 4ICD activity in the cytosol. 4ICD contains motifs 
similar to pro-apoptotic BH3 proteins and localises in mitochondria 
and the endoplasmic reticulum; also its anti-tumour activity is at-
tenuated by the caspase inhibitor zVAD, suggesting that it is a bone 
??? apoptosis inducer. In support of this function, an association 
between cytosolic expression of 4ICD and apoptotic cells was noted 
in human breast cancers (Jones, 2008). A unifying hypothesis to 
explain these disparate functions has been proposed whereby in 
early stages of breast cancer development, ligand (mainly HRG?) 
activation of Erb-B4 generates nuclear 4ICD. ER+ cells have a 
growth advantage and a 4ICD-dependent autocrine loop develops, 
shifting from a Stat5 co-activator of differentiation to an ER? co-
activator driving proliferation. At later stages both ER? and Erb-B4 
may be lost, perhaps being redundant in the face of additional 
even stronger oncogenic drivers (Jones, 2008). These intriguing 
possibilities (and their therapeutic implications) are currently being 
actively investigated.
These varying associations between the Erb-B receptors and 
breast cancer biology are interesting as they may echo their 
contrasting roles in mammary gland development: promoting cell 
proliferation/’invasion’ of ductal epithelial cells into the mammary fat in 
the case of EGFR/Erb-B2/3 and a function in epithelial differentiation 
for Erb-B4 (Stern, 2008). It may be that subsets of precursor cells, 
???????????????????????????????????????????????????????????????
trapped in that phenotype, unresponsive to normal regulatory cues.
Ligands and downstream signalling pathways in breast 
cancer
Given the importance of the ADAM17-AREG/TGF?-EGFR axis in 
normal mammary development, it is not surprising that all of these 
elements – and those that they regulate such as additional proteases 
and growth factor signalling pathways - are misregulated in breast 
cancers. ADAM17, AREG and TGF??????????????????????????????
with co-expression of TGF? and EGFR being associated with par-
ticularly poor prognosis. Antisense suppression of AREG reduced 
the tumorigenicity of immortalised human mammary epithelial cells 
and prevented EGFR becoming activated in response to exogenous 
ligands (Ma et al., 2010). 
In an interesting series of experiments with human mammary 
epithelial cells at different stages of transformation from immor-
talised – premaligant - tumorigenic, it was shown that progression 
was associated with upregulation of AREG and TGF?, rendering 
them independent of exogenous EGF. In 3D cultures, reversion to a 
non-malignant phenotype was achieved by inhibitors of proteolytic 
activity or EGFR, suggesting an autocrine MMP/ADAM-dependent 
EGFR activation pathway. Similar effects were achieved by ADAM17 
siRNA (Kenny and Bissell, 2007), suggesting that this protease may 
be a good therapeutic target in EGFR-dependent breast cancers.
Angiogenesis, invasion and metastasis
?????????????????????????????????????????????????????????????????
and/or stimulate de novo angiogenesis in order to grow progres-
sively. The newly formed vasculature is leaky and provides a 
ready conduit for haematogenous dissemination. One of the 
major angiogenic growth factors is VEGF, which is upregulated 
not only by hypoxia, but also via the Erb-B oncogenes, likely via 
the PI3K-AKT signalling pathway. Erb-B2 and EGFR overexpres-
sion tends to correlate with increased levels of VEGF A (and also 
lymphangiogenic cytokines VEGF C and D) and in some cases 
with higher microvessel density. 
Hypoxia itself is a known adverse prognostic indicator, and many 
HIF-responsive genes (such as MMPs, CXCR4, c-MET, LOX) 
are implicated in angiogenesis and metastasis. In the case of the 
G-protein-coupled chemokine receptors such as CXCR4, and its 
ligand CXCL12/SDF-1?, their expression and activation has also 
been linked to site-selective metastasis. Erb-B2 and CXCR4 levels 
tend to correlate in breast cancers, and the former is reported to 
enhance CXCR4 expression and to inhibit ligand-induced degra-
dation. Interestingly, inhibition of CXCR4 expression suppressed 
Erb-B2-mediated malignant potential suggesting a mechanistic 
linkage between the two signalling axes.
In order to metastasise, cells must detach from underlying ex-
???????????? ????????????????????????????????????????????????????????
anchorage independent conditions, and demonstrate the ability to 
invade surrounding tissues and basement membranes. Invasion 
????????????????????????????????? ??????????????? ???????????????
??????????????????????????????????????????????????????????????????
motility has also been described. An early manifestation of breast 
cancer is the ability of transformed but premalignant cells to 
proliferate within the ductal lumen, away from their natural ECM 
niches. Detachment usually induces downregulation of EGFR (and 
cell death) but this can be overcome by Erb-B2, which stabilises 
EGFR and ?1 integrin via Erk-Sprouty2 signalling and a lowered 
??????????? ???????????? ???? ???? ???????????????????????????????
?????????????????????????????(Grassian et al., 2011). 
Erb-B2 and EGFR are also recognised as activating key signal-
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ling pathways promoting cell motility; indeed EGFR ligands are 
very potent chemotactic factors, stimulating rapid migration along 
concentration gradients. AIB1/SRC3 is associated with breast 
??????????????????????????? ??????? ???????? ???????????????????
NRG-Erb-B2 mediated motility, co-operating with Erb-B2 to in-
duce progression of DCIS to invasive ductal carcinoma. Erb-B2 
reportedly selectively promotes MDA-MB-468 migration mediated 
by EGF via phosphorylation of tyr1248 and a transient activation of 
PLC?. Others have implicated Tyr1227 and Shc-Memo signalling in 
response to HRG in T47D cells, although in both cases PLC? was 
an important contributor. HRG?????????? ?????????? ???? ????????????
enhances metastasis via PI3 kinase signalling, since mutation of 
its six YXXM PI3K p85-binding domains inhibited breast carci-
noma cell motility, invasion, vascular intravasation and invasion 
(Smirnova et al., 2011).
Overall, EGFR/Erb-B signalling has been linked to all aspects 
of metastasis: stimulation of angiogenesis, alterations in cell-cell 
and cell-matrix adhesion, upregulation of proteases and other key 
?????????????????? ????? ??????????????????? ????????????????????
extravasation and organ-selective colonisation (Eccles, 2001) (Fig. 
Organotropism and site selectivity of metastasis
The commonest site of breast cancer metastasis is the bone, 
??????????????? ????????????????????????????????????????????????????
and host cells that perpetuates tumour cell colonisation, metastasis 
development and bone destruction (Guise, 2010). Although there 
??????????????????????????????????????????????????????????????????
Erb-B receptors (or their ligands) in bone metastases – and indeed 
Erb-B2 seems to be under-represented – there is good evidence 
of a role for ligand-activated proteases in the bone microenviron-
ment (Foley et al., 2010). 
Seminal work by Massague’s group deciphered the genetic 
determinants underlying key phases of metastasis in the MDA-
MB-231 breast carcinoma model: escape from the primary tu-
mour, extravasation and growth at secondary sites. Sublines with 
???????? ???? ???????? ?????? ??????? ?????? ???????????? ????????? ????
their key characteristics analysed. Osteoclast activity in the bone 
microenvironment is regulated by a balance between RANKL and 
osteoprotegerin (OPG). The presence of breast cancer cells upsets 
this balance, leading to a net increase in bone destruction via os-
Primary tumour            Dissemina?on              Secondary sites
AREG/EGF released by ADAMs from tumour cells (together with 
PTHrP) activate osteoblasts (OB). OB secrete RANKL and 
activate osteoclasts (OC), which release EGFR ligands from 
stroma, stimulating tumour growth
Erb-B2+ cells show preferential localisation/growth in marrow
Bone
Bone 
marrow
Brain
Lung
Liver
EGFR/Erb-B2 - angiogenesis           Erb-B2 –  motility
- invasion                   Erb-B2/CXCR4- directional migration
- proteolysis Erb-B2/EGFR/EREG/HB-EGF extravasation
Erb-B3 - intravasation ?TGF activates MSC in metastatic “niche”
EGFR/Erb-B2 - protection from anoikis
HB-EGF promotes extravasation across BBB
Erb-B2/ErbB3 heterodimers respond to local NRGs
Erb-B2 promotes outgrowth of micrometastases
EREG promotes extravasation in lung microvasculature
EGFR+ tumour cells proliferate in response to high 
levels of  EGF and EREG
EGFR+ tumour  cells proliferate in  response to high 
levels of TGF?
Fig. 3. Role of EGFR/Erb-B receptors and ligands 
in metastasis and organotropism. Most if not all 
of the Erb-B family have been linked to an increased 
probability of breast cancer metastasis and, in some 
cases to site-selective growth. At the primary tumour 
site, EGFR and Erb-B2 in particular regulate factors 
that promote angiogenesis and invasion. Protection 
from anoikis and motility contribute to the ability of 
tumour cells to survive in the circulation, and speciﬁc 
ligands promote extravasation through the specialised 
microvasculature of different organs. There is limited 
involvement in the early generation of ‘pre-metastatic 
niches’, but ﬁnally, tumour cells expressing EGFR or 
Erb-B receptors respond to local growth factors to 
generate overt metastases. OB = osteoblasts, OC= 
osteoclasts.
3). There is now a growing appreciation that 
bone-marrow-derived mesenchymal stem cells 
(MSC) are recruited to the stroma of developing 
tumours and also contribute to formation of the 
?????????????????????????? ????????????????????
tumour cell-derived TGF? simulated release of 
angiogenic factors and induced breast carci-
noma cell migration; another example of mutual 
Erb-mediated tumour-host interactions involved 
in tumour progression (De Luca et al., 2011). 
Dissemination to lymph nodes is a key factor 
in breast cancer staging, but increasingly iden-
????????????????????????????????????????????????
the blood and in bone marrow aspirates is also 
being linked to poor prognosis. These cells 
??????????? ??????????? ???? ??? ????????????
when the primary tumour is negative)(Braun et 
al., 2001). Such observations have led to the 
acceptance that dissemination may be a much 
earlier event than originally appreciated (Eccles 
and Paon, 2005) and that the Erb-B proteins, 
???????????????? ??????????????????????????????
tumour cell escape, motility and dissemination. 
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????????????????????????????????????????????????????? ?????????????
stimulate growth and invasion of the tumour (Kang et al., 2003). 
Ligands such as EGF or AREG shed by tumour cells activate 
EGFR-expressing osteoblasts to secrete less OPG; simultane-
ously autocrine stimulation releases PTHrP from tumour cells to 
the same end, and the osteoblasts in turn release EGFR ligands 
and perpetuate the cycle of monocyte-derived osteoclast activation 
via RANKL or MCP and thus bone destruction (Foley et al., 2010). 
PTHrP has been recognised as one of the “metastasis virulence 
factors” within a bone metastasis gene signature. It transcription-
ally regulates AREG and to a lesser extent TGF? and HB-EGF, 
and may also increase ligand shedding via ADAM17. MMP1 and 
ADAMTS-1, additional members of the 11-gene signature, also 
increase AREG shedding and bone metastasis. Although MDA-
MB-231 represents an ER? negative breast cancer, since AREG 
is regulated by oestrogen, this pathway could be of more general 
???????????? ??? ??????? ???????? ????????? ??? ???????? ??? ??? ?????
whether EGFR inhibitors will have an impact, alone or in combina-
tion, against bone metastasis. 
A degree of organotypic metastasis selection is determined by 
the ability of tumour cells to extravasate through the phenotypically-
????????????????????????????????????????????????????? ??????????
???????????????????????????????????????????????????????????????????
barrier to tumour cell colonisation; however the lung endothelium 
has tight junctions and the blood-brain barrier (BBB) is even further 
specialised. EREG, together with COX-2, MMP-1 and ANGPTL4 
has been linked to an enhanced capacity of breast tumour cells to 
extravasate in the lungs since together they can compromise the 
integrity of the pulmonary microvasculature. In contrast, HB-EGF, 
??????????????????????????2,6-sialyltransferase ST6GALNAC5 
were strongly associated with breast cancer brain metastases 
(Bos et al., 2009) (Fig. 3). 
The predilection of breast cancers expressing Erb-B oncogenes 
to metastasise to the brain may also be due to the fact that their 
cognate ligands (NRGs) are neural growth factors. It has been 
shown experimentally that Erb-B2 overexpression increases the 
outgrowth of breast cancer cells in the brain, rather than the initial 
???????? ?????????? ???? ?????????? ??????????????????? (Palmieri 
et al., 2007). The co-association of CXCR4 and Erb-B2 may be 
linked to visceral metastases, and similarly cells overexpressing 
EGFR could respond to the high levels of ligands such as TGF? 
and EREG in liver and lung (Eccles and Welch, 2007) (Fig. 3).
Therapy targeting the EGFR/Erb-B family
EGFR and Erb-B2 have been the main receptors considered 
as targets for immunotherapeutic approaches in breast cancer, 
mainly via antibody-based therapies, but also in active immunisation 
and gene therapy protocols, as well as ligand-targeted toxin and 
antisense/RNAi approaches and anti-Erb-B2 vaccines (Ladjemi 
et al., 2010) (Table1; Fig. 4).
A novel means of inhibiting Erb-B expression and function is via 
HSP90 chaperone inhibitors such as 17-AAG and NVP-AUY922. 
HSP90 levels correlate with poor prognosis in breast cancer and 
????????????????????????????????????????????????????????????????????-
pendent on HSP90 for its correct folding and cellular localisation. 
HSP72, a related chaperone, has also been shown to be essential 
for Erb-B2-driven oncogenesis in transgenic mouse models by 
Agent Type Target(s) Comments 
Trastuzumab (Herceptin) and T-DM1 Humanised IgG1 monoclonal antibody Erb-B2 juxtamembrane region (domain IV) Approved for Erb-B2+ MBC and node+ early stage disease. Also 
conjugated to DM1, (maytansine toxin) for targeted delivery. Phase 
III. Active in trastuzumab-resistant cells 
Pertuzumab (Omnitarg) Fully humanised IgG1 monoclonal 
antibody 
Erb-B2 dimerisation domain (II) Inhibits dimerisation with EGFR and Erb-B3. Phase III breast 
cancer 
Cetuximab (Erbitux) Chimaeric IgG1 monoclonal antibody EGFR ECD Little activity in EGFR+ breast cancer 
Panitumumab (Vectibix) Fully human IgG2 monoclonal antibody EGFR ECD Little activity in EGFR+ breast cancer 
Ertumaxomab Bispecific monoclonal antibody Erb-B2 and Fc?RI/III Promotes ADCC via T cells. Phase II breast cancer 
Gefitinib (Iressa) Reversible TKI (quinazoline) EGFR kinase domain Limited activity in breast cancer 
Erlotinib (Tarceva) Reversible TKI 
(quinazoline) 
EGFR kinase domain Limited activity in breast cancer 
Lapatinib (Tykerb) Reversible TKI  
4-anilinoquinine  
EGFR/Erb-B2 kinase domain Response linked primarily to Erb-B2 overexpression.  
Neratinib  
(HKI-272) 
Irreversible TKI Pan-Erb-B 
kinase domain 
Active in cells with EGFR and Erb-B2 mutations. Phase I/II + 
temsirolimus in Erb-B2+ or TNBC 
Afatinib (BIBW-2992) Irreversible TKI EGFR/Erb-B2 
kinase domain 
Active in trastuzumab-resistant breast cancer. Plans to trial in 
inflammatory BC and in several combinations 
Canertinib  
(CI-1033) 
Irreversible TKI Pan-Erb-B 
kinase domain 
Phase II results poor in lung and ovarian cancer 
AEE788 Reversible TKI EGFR, Erb-B2 VEGFR Added benefit with letrozole in preclinical breast cancer models. 
Phase I/II in other cancer types 
BMS-599626 
(AC480) 
Reversible TKI EGFR/Erb-B2 kinase domain Inhibits EGFR-ErbB2 heterodimers. Phase I  
Arry-334543 Reversible TKI EGFR/Erb-B2/B4 
kinase domain 
Phase II in breast cancer 
MM-111 Bispecific fusion protein Blocks Erb-B3 ligand binding  Targets ErbB2-B3 heterodimers 
Tanespimycin (17-AAG) Ansamycin HSP90 chaperones Targets ErbB2, AKT, VEGFR, ER?. Phase III breast  
Retaspimycin 
(IPI-504) 
Ansamycin HSP90 chaperones Targets ErbB2, AKT, VEGFR ER?, Phase II breast 
NVP-AUY922 Isoxazole resorcinol HSP90 chaperones Targets ErbB2, AKT, VEGFR, ER?. Phase I/II breast 
BIIB 021 Purine scaffold HSP90 chaperones Phase II in ER+ MBC + Exemestane 
TABLE 1
EXAMPLES OF THERAPIES TARGETING THE EGFR/ERB-B FAMILY
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regulating senescence signalling pathways (Meng et al., 2011). 
Other key client proteins are also important in breast tumour 
development (e.g. ER?) and progression, for example: AKT in 
cell survival and resistance to multiple agents; VEGF receptors 
in angiogenesis/lymphangiogenesis; FAK, Src and MET in inva-
sion - to name but a few. HSP90 inhibitors induce depletion and 
proteasomal degradation of Erb-B2 and other client proteins in 
vitro and in vivo, resulting in potent antitumour and antiangiogenic 
activity in preclinical tumour models (Eccles et al., 2008), most 
notably in ER?+/Erb-B2+ BT474 xenografts. Recent clinical trial 
data in MBC where patients had progressed on trastuzumab are 
very promising (Modi et al., 2011). In preclinical and clinical stud-
ies, trastuzumab labelled with positron-emitting isotopes has also 
been used to monitor responses as described later in this review.
Inhibiting ligand binding/dimerisation
The anti-EGFR antibody cetuximab has been tested in combina-
tion with a variety of standard chemotherapeutic agents in breast 
??????? ????????? ??????? ??????? ???? ?????? ???????????????? ?????
fact that Erb-B2 positive tumours have a predilection for colonising 
the brain and because antibodies fail to cross the BBB effectively. 
Pertuzumab is another humanised antibody that inhibits Erb-B2 
heterodimerisation with other family members by binding to the 
dimerisation loop of the former (i.e a different site from trastuzumab). 
It has shown some promise in Erb-B2+ breast and ovarian cancer 
patients and is also being evaluated in combination with trastuzumab 
and chemotherapy (CLEOPATRA trial) (Baselga and Swain, 2010). 
In general, Erb-B2 targeted therapies are only effective in cancers 
????????????????????????????????????????????????????????????????-
mine those eligible (e.g. HercepTest or Oncotype Dx). Antibodies 
to Erb-B2 have also been employed to measure expression levels 
in tumours and also to monitor responses to therapy using positron 
emission tomography (PET) or Erb-B2-targeted nanoparticles in 
MRI approaches, since they report non-invasively on the level of 
membrane-exposed receptor (Capala and Bouchelouche, 2010). 
Similarly, ELISA or dot-blot assays can be performed on plasma 
samples to monitor the levels of Erb-B2 ECD and also reportedly 
correlate with tumour levels in several studies.
Advances in antibody-based therapies include the targeting of 
toxicity. Cetuximab is a chimeric IgG1, 
whereas panitumumab is a fully human 
IgG2 anti-EGFR monoclonal antibody 
?????????????????????????????????????????
in breast cancer (Burness et al., 2010).
Trastuzumab, a humanised anti-Erb-
B2 monoclonal antibody targeting the 
juxtamembrane region of the extracellular 
domain, has been more successful in 
clinical trials, particularly in combination 
with standard chemotherapy and in the 
adjuvant setting (Goel et al., 2011). This 
sensitisation to chemotherapy may involve 
downregulation of Mcl-1, an antiapoptotic 
protein and/or activation of PTEN which 
dephosphorylates AKT (a key survival 
signal) thereby promoting cell death. 
Trastuzumab is reportedly most active in 
tumours driven by Erb-B2 homodimers 
and is also effective in combination with 
antiendocrine therapies in ER+ tumours. 
Given the many key cellular functions 
activated downstream of Erb-B signalling, 
it is not surprising that trastuzumab (and 
other Erb-B-targeted therapies) also inhibit 
angiogenesis, which could contribute indi-
rectly to tumour responses. Combinations 
of trastuzumab with bevacizumab, an 
antibody targeting the major angiogenic 
cytokine (VEGF) are also being trialled.
In addition to direct inhibition of Erb-B2 
function, e.g. by promoting its internalisa-
tion and degradation, trastuzumab can pro-
mote antibody-directed cellular cytotoxicity 
(ADCC) mediated by natural killer (NK) 
cells. Interestingly (but unfortunately) an 
increase in the incidence of brain metasta-
ses has been observed in patients treated 
?????????????????? ???? ?????????? ????????
Fig. 4. Key EGFR/Erb-B signalling pathways and sites of action of therapeutic agents. The ﬁgure 
illustrates monoclonal antibodies, small molecule kinase inhibitors and other agents (e.g. chaperone 
inhibitors) and their mechanisms of action in breast cancer cells and the associated vasculature.
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prodrug activating enzymes or nanoparticles carrying cytotoxic 
payloads (Colombo et al., 2010). Recently, complexes of a com-
pact human anti-Erb-B2 antibody and cytotoxic human pancreatic 
RNase have shown promise in vitro and in vivo in a rodent breast 
tumour model (Borriello et al., 2011). In experimental systems, it 
has been shown that using combinations of anti-Erb-B2 antibod-
ies recognising different epitopes are more effective at inhibiting 
ligand-mediated invasion than single agents.
Inhibiting kinase activity
Several reversible and irreversible SMTKI with varying degrees 
of selectivity have been developed. These small molecule agents 
compete with ATP binding in the kinase domain of the receptor and 
inhibit downstream signalling. The most well known are the EGFR 
??????????????????????????????????????????????????????????????????
inhibitor lapatinib and the more recently developed irreversible 
inhibitor afatinib.
????????? ??? ????????? ???? ??????????????? ??? ?????? ????? ????????
in breast cancer, even in triple negative cases which often have 
high levels of EGFR. Several trials are underway where EGFR 
TKI are used in combination with other cytotoxic or molecularly 
targeted agents.
Lapatinib binds the ATP-binding pocket of both EGFR and Erb-
?????????????????????????????????????????????????? ???????????????
or rapid development of resistance to monotherapies. Unlike 
trastuzumab, activation of the PI3K pathway does not seem to 
? ???????????????????????????????????????????????????????????? ????
both cytotoxic and molecularly targeted agents. Combination with 
trastuzumab improved median progression-free survival and re-
duced the risk of disease progression in a phase III trial of heavily 
pre-treated patients and it has also been approved for use in those 
who have failed trastuzumab. Most responses have been seen in 
??????????????????????????????????????????????????? ?????????????????
triple negative or EGFR-positive cancers (Burness et al., 2010). 
Neratinib is another orally active agent which irreversibly inhibits 
the kinase activity of EGFR, Erb-B2 and Erb-B4 which has shown 
promise in previously untreated and also trastuzumab-resistant 
breast cancers (Colombo et al., 2010). It is also being trialled in 
combination with paclitaxel, capecitebine and vinorelbine. 
Links between Erb-B signalling and resistance to therapy
EGFR activation has been linked to resistance to the anti-
endocrine agent tamoxifen, possibly via phosphorylation of AIB1, 
an ER? co-activator which can result in mitogenic (rather than 
inhibitory) activity. Phosphorylation of ER? (which can be achieved 
by several upstream kinases including Erb-B2) can also lead to 
oestrogen-independent transcription of ER? targets, also resulting 
in resistance to tamoxifen. There is cross talk between ER?, c-Src, 
EGFR, and STAT5b in ER+ breast cancer cells and increased 
EGFR and c-Src signaling is associated with tamoxifen resist-
ance. Constitutively active STAT5b increased DNA synthesis and 
conferred tamoxifen resistance in ER+ human breast carcinoma 
cell lines. Cells exposed to a pure anti-oestrogen (fulvestrant) ac-
????????????????????????????????????????????????????????????????
and phosphorylation of EGFR and Erb-B2, together with TGF? 
and AREG expression. More recently, fulvestrant has also been 
shown to upregulate Erb-B3 and/or Erb-B4 and to sensitise cells to 
NRG?1 (Hutcheson et al., 2011). It is possible, therefore, that mito-
genic autocrine signalling via any or all of the Erb-B receptors may 
subsume the role of oestrogen during breast cancer progression. 
EGFR activation stimulates signalling via AKT and ERK, and 
has been linked to multidrug resistance via upregulation of MRP-
1,3,5 and 7. Erb-B3 (and also Erb-B4) has also been linked to 
resistance to anti-endocrine therapy (Sutherland, 2011) and to 
paclitaxel, reportedly by upregulating survivin via the PI3K-AKT-
mTOR pathway. Amphiregulin expression has been associated with 
resistance to cisplatin in MCF7 cells and in patients via enhanced 
EGFR, AKT and ERK1 activation. EGFR and Erb-B2 activation 
may also be involved with resistance to radiotherapy, since both 
are upregulated/activated following exposure to ionising radiation. 
?????????????????????????????????????????????????????????
targeted therapies have been described, including subversion of 
trastuzumab binding to Erb-B2 by shed p95 ECD fragments (Ar-
ribas et al., 2011); a switch to alternative signaling via other Erb-B 
family members (notably Erb-B3), alternative RTK such as c-MET, 
??????????????????????????????????????????????????????????????-
ments (e.g. PI3 kinase-AKT-FOX1A) for example via loss of PTEN 
or by PIK3CA mutations. (Garrett and Arteaga, 2011). In the early 
days, the development of host antibodies against the therapeutic 
antibody could neutralise their activity upon repeat administration. 
However this has now largely been overcome by the development 
of humanised (or fully human) therapeutic antibodies. 
In addition, there is evidence of primary resistance (or lack of 
sensitivity) in many patients, in spite of the fact that their tumours 
overexpress the target receptor, although the reasons for this – which 
are likely to be many and various – are less well understood. One 
mechanism may involve negative feedback loops in cases where 
trastuzumab fails to abolish Erb-B2 phosphorylation. This may occur 
due to trans-phosphorylation by other Erb-B receptors, following 
an AKT-dependent ADAM17-mediated release of Erb-B ligands 
(Gijsen et al., 2010)?????????????????????????????????????????????
a common mediator of multiple trastuzumab resistance pathways 
??? ???? ???????? ???de novo trastuzumab-resistant cells, involving 
dephosphorylation by PTEN. Increased c-SRC activation conferred 
resistance in breast cancer cells and correlated with trastuzumab 
refractoriness in patients. Targeting c-SRC re-sensitized cells to 
trastuzumab and eliminated trastuzumab-resistant tumours in vivo, 
suggesting a potential clinical application of this strategy (Zhang 
et al., 2011). 
Molecular mechanisms of resistance to small molecule inhibi-
tors generally differ from those linked to refractoriness to antibody 
therapy. In the former case, mutations in the kinase domain of 
????????????????????????????????????????????????????????????
in the latter case, as described above, downregulation of the 
primary molecular target, a shift to non-inhibitable dimers (such 
as Erb-B2-IGF1R) or a short-circuit of the downstream signalling 
pathways is more common. Other reported resistance mechanisms 
include a mutation in exon 21 of the HER2 gene that encodes a 
?????????????????????????????????????????????????????????????????
MUC4, a membrane-bound glycoprotein which binds Erb-B2 and 
can compete with trastuzumab binding. 
Future strategies will need to include rational combinations of 
therapeutic agents to overcome (or pre-empt) resistance. Research 
laboratories developing new targeted agents are deliberately 
?????????????????????????????????????????????????????????????????
future likely escape mechanisms of cancers in the clinic. These 
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cells are then subjected to microarray or to proteomic analysis to 
uncover the mechanisms of resistance. If this reveals a mutated 
target (as in the case of EGFR), then screens can be performed to 
identify new compounds which can bind the altered conformation; 
??????????????????????????????????????????????????????????????????????
agents or siRNA libraries can be used to identify new vulnerabilities 
(Achilles’ heels) in the resistant cells which may be exploitable as 
targets. One good example is the multikinase inhibitor dasatinib, 
which shows synergistic anti-proliferative activity with trastuzumab 
in Erb-B2 expressing BT474 human breast carcinoma cells both 
in vitro and in vivo (Seoane et al., 2010). Since one of the kinase 
targets of dasatinib is c-SRC, this protocol may also help to prevent 
development of resistance as outlined in the previous section.
 
Cancer stem-like cells (CSC)
Cells which express one or more supposed markers of stem 
cells (e.g. CD44+/CD24- ALDH1+ and with their phenotypic char-
acteristics (self-renewal capacity, anchorage-independent growth, 
pluripotency) have been isolated from mammary glands and breast 
cancers. It has been proposed that such cells may represent the 
true seeds of cancer, contributing to drug resistance (due to expres-
??????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????
CSC may be endocrine resistant because they express low levels 
of ER??? ?????????????? ??????????????????????????????????????????
clonogenicity of CSC derived from cancers and DCIS in soft agar, 
and overexpression of Erb-B2 in MEC increases the proportion of 
cells with CSC properties. Normal breast epithelial stem cells are 
highly dependent on EGFR and other RTK, raising the possibil-
ity that their increased expression in endocrine-resistant breast 
????????????????????????????????????????????????????????????????
endocrine therapies. Several studies show that breast CSCs are 
ER?+/EGFR+/Erb-B2+, supporting this view (O’Brien et al., 2011). 
These observations suggest that Erb-B2 and/or EGFR inhibitors 
could target the CSC population, and indeed one small study with 
?????????????????????????????????????????????????????????????????????
of CD44+/CD24- cells in breast cancer biopsies (Schmidt, 2008). 
???????????????????????????????????????????????????????????????????
perhaps shed early in cancer progression, may remain dormant and 
refractory to therapy until reactivated, when they may contribute to 
treatment relapse and metastasis. There is no doubt that we will 
need to pay more attention to the genotypic phenotypic properties 
of pre-existing micrometastases if we are ever to provide robust 
and sustained control of disseminated breast cancer.
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